Research Papers

This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.

Tag: Drug-Sensitivity Testing

Displaying 6 papers

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fl uoroquinolones: results from a multicountry surveillance project

Publication: Zignol, Matteo, Anna Dean, and Natavan Alikhanova. "Population-based Resistance of Mycobacterium Tuberculosis." The Lancet (Published Online July 7, 2016 Http://dx.doi.org/10.1016/S1473-3099(16)30190-6):

7/2016

Tags: Drug-Sensitivity Testing, MDR-TB, Moxifloxacin, Pyrazinamide, TB Burden

Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility

Publication: Streicher EM, Maharaj K, York T, et. al. Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility.J Clin Microbiol. 2014 Nov;52(11):4056-7. doi: 10.1128/JCM.02438-14

8/2014

Tags: Drug-Sensitivity Testing, MDR-TB, Pyrazinamide

Aligning New Tuberculosis Drug Regimens and Drug Susceptibility Testing- A Needs Assessment and Roadmap for Action

Publication: Wells WA, Boehme CC, Cobelens FGJ, et. al. Aligning New Tuberculosis Drug Regimens and Drug Susceptibility Testing: A Needs Assessment and Roadmap for Action. Lancet Infect Dis. 2013;13(5):449-458. doi:10.1016/S1473-3099(13)70025-2.

3/2013

Tags: Advocacy, Drug-Sensitivity Testing, Editorials, TB Market

New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future

Publication: Lienhardt C, Raviglione M, Spigelman M, et. al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012 May 15;205 Suppl 2:S241-9. doi: 10.1093/infdis/jis034.

3/2012

Tags: Advocacy, Childhood TB, Clinical Development, Drug Discovery, Drug-Sensitivity Testing, Editorials, Global Pipeline, MDR-TB, Moxifloxacin, Pharmacodynamics, Pharmacokinetics, Policy, Preclinical Models, Pretomanid/PA-824, Regimen Change, TB Market, TB-HIV, Trial Design

Moxifloxacin for tuberculosis

Publication: Mendel C, Springsklee M. Moxifloxacin for tuberculosis. Lancet Infect Dis. 2012 Mar;12(3):176-7; author reply 177-8. doi: 10.1016/S1473-3099(11)70351-6.

3/2012

Tags: Advocacy, Clinical Development, Drug-Sensitivity Testing, Editorials, MDR-TB, Moxifloxacin, Policy, Regimen Change

Implications of the current tuberculosis treatment landscape for future regimen change

Publication: Wells WA, Konduri N, Chen C, et.al. Implications of the current tuberculosis treatment landscape for future regimen change. Int J Tuberc Lung Dis. 2011 Jun;15(6):746-53. doi: 10.5588/ijtld.10.0094.

6/2011

Tags: Drug-Sensitivity Testing, HRZE, MDR-TB, Policy, Regimen Change, TB Market